Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.47 +0.4% CAM 0.330 −1.5% SYH 0.398 −1.9% LOT 0.040 +0.0% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.47 +0.4% CAM 0.330 −1.5% SYH 0.398 −1.9% LOT 0.040 +0.0%
Other

Microbix Launches New Products to Support H3N2 Flu Testing

By The Northwire Desk — AI Analysis Dec 10, 2025 · 07:00 MBX · 0.24 MICROBIX BIOSYSTEMS INC. J
MBX · Price

Executive Summary

  • Microbix Biosystems announced the commercial launch of its QAPs™ quality assessment products and QUANTDx™ reference materials for H3N2 Influenza A testing.
  • The new QAPs are available on Copan® FLOQSwabs® in RUO (PROCEEDx®) and IVD (REDx®) formats, offering multi‑year room‑temperature stability for assay training, validation, and performance verification.
  • H3N2 reference materials can be supplied on request to support limit‑of‑detection, sensitivity, and specificity studies for assay developers and regulatory submissions.

Key Details

  • Product Offering: QAPs™ (quality assessment products) for H3N2, packaged with existing H1N1 four‑plex formulation; available as PROCEEDx® (RUO) or REDx® (IVD).
  • Reference Materials: QUANTDx™ line now includes H3N2 reference materials for analytical performance characterization.
  • Target Users: Clinical laboratories, diagnostic developers, accreditation organizations, and testing sites needing validated sample mimetics.
  • Stability & Distribution: Multi‑year room‑temperature stability; distributed globally via Copan® FLOQSwabs®.
  • Epidemiological Context: Launch timed with emergence of H3N2 subclade K as dominant strain for the 2025/26 flu season, addressing antigenic drift concerns that can impair assay accuracy.
  • CEO Quote: Cameron Groome emphasized the importance of timely QAP availability to support public‑health responses and highlighted Microbix’s role as a Canadian‑led company delivering Ontario‑made healthcare solutions.
  • Company Background (relevant facts): Over 120 employees; FY2024 revenue C$25.4 million; products sold in >30 countries; ISO 9001 & 13485 accredited, FDA registered, CE marked.

Notable Quotes

“We believe it’s critical that Microbix creates QAPs for emerging infectious diseases in a timely manner. Effective public health responses to all outbreaks are predicated on accurate and reliable tracking, screening, and diagnosis – needs that are imperiled when quality management tools to support testing aren’t readily available.” – Cameron Groome, CEO & President

All forward‑looking statements are subject to risks and uncertainties as described in the release.

Read the original news release →

More from MICROBIX BIOSYSTEMS INC. J

May 14, 2026 · 08:01

Microbix Revenue Plunges on China Sales Collapse; Cash Burn Concerns Mount Despite Q2 Stabilization

Earnings Apr 27, 2026 · 07:00

Microbix Product Validation Fails to Offset Revenue Decline and Cash Burn Concerns

Other Apr 15, 2026 · 07:00

Microbix Biosystems Showcases HCV Mimetic as Revenue Contracts Shrink and Cash Burn Accelerates

Other Mar 17, 2026 · 07:00

Microbix Presents Reference-Material Innovations at EUROGIN

Drill Results Mar 10, 2026 · 16:13

Microbix partner Sequel continues work on Kinlytic

Production / Operations Mar 10, 2026 · 07:00

Microbix's Clot-Buster Drug Project Advances

Production / Operations